Related Experiment Video

Updated: May 19, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for

J Fichna1, A Mokrowiecka, A I Cygankiewicz

  • 1Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada.

Neurogastroenterology and Motility
|August 14, 2012
PubMed

Insights

Transient Receptor Potential Vanilloid 4 (TRPV4) is upregulated in inflammatory bowel diseases (IBD). Blocking TRPV4 alleviates colitis and pain, suggesting it as a therapeutic target for IBD.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Emerging evidence links Transient Receptor Potential Vanilloid 4 (TRPV4) activation in the gut to inflammation.
  • The specific role of TRPV4 in inflammatory bowel diseases (IBD) remains largely unexplored.

Purpose of the Study:

  • To investigate the expression of TRPV4 in IBD patients.
  • To evaluate the therapeutic potential of TRPV4 blockade in an experimental model of colitis.

Main Methods:

  • Quantitative analysis of TRPV4 mRNA expression in IBD patient samples.
  • Administration of a selective TRPV4 antagonist in the 2,4,6-trinitrobenzenesulfonic acid-induced colitis model in animals.

Main Results:

  • TRPV4 mRNA expression was significantly increased in patients with inflammatory bowel diseases.
  • Selective TRPV4 blockade markedly reduced colitis severity and associated pain in the animal model.
  • These findings highlight the involvement of TRPV4 in the pathophysiology of intestinal inflammation.

Conclusions:

  • TRPV4 is upregulated in inflammatory bowel diseases.
  • Targeting TRPV4 offers a promising strategy for managing intestinal inflammation and pain in IBD patients.
  • TRPV4 represents a potential therapeutic target for novel anti-inflammatory treatments in IBD.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...